tiprankstipranks
Advertisement
Advertisement

JP:4591 Stock Latest News

Ribomic Widens Losses but Boosts Liquidity as It Projects Deeper Red Ink
Company AnnouncementsRibomic Widens Losses but Boosts Liquidity as It Projects Deeper Red Ink
2d ago
4591
RIBOMIC Files IND for Phase III Trial of Achondroplasia Drug in Japan
PremiumCompany Announcements
RIBOMIC Files IND for Phase III Trial of Achondroplasia Drug in Japan
2M ago
4591
Ribomic’s Achondroplasia Drug Hits Phase II Height-Growth Goal, Paving Way for Phase III
PremiumCompany Announcements
Ribomic’s Achondroplasia Drug Hits Phase II Height-Growth Goal, Paving Way for Phase III
2M ago
4591
RIBOMIC Posts Continued Losses but Maintains Strong Equity Base in Nine-Month Results
PremiumCompany Announcements
RIBOMIC Posts Continued Losses but Maintains Strong Equity Base in Nine-Month Results
3M ago
4591
Ribomic Files Patent for High-Activity Eye-Disease Aptamer RBM-006 After Positive Diabetic Retinopathy Data
PremiumCompany Announcements
Ribomic Files Patent for High-Activity Eye-Disease Aptamer RBM-006 After Positive Diabetic Retinopathy Data
4M ago
4591
RIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment
PremiumCompany AnnouncementsRIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment
6M ago
4591
Ribomic Inc. Reports Six-Month Financial Results with No Revenues
Premium
Company Announcements
Ribomic Inc. Reports Six-Month Financial Results with No Revenues
6M ago
4591
RIBOMIC Reports Successful Phase II Trial for Achondroplasia Treatment
Premium
Company Announcements
RIBOMIC Reports Successful Phase II Trial for Achondroplasia Treatment
7M ago
4591
RIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment
PremiumCompany Announcements
RIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment
7M ago
4591
RIBOMIC Discovers New Treatment Potential for Diabetic Retinopathy
PremiumCompany Announcements
RIBOMIC Discovers New Treatment Potential for Diabetic Retinopathy
8M ago
4591
RIBOMIC Reports Sustained Efficacy of Umedaptanib Pegol in Achondroplasia Trial
PremiumCompany Announcements
RIBOMIC Reports Sustained Efficacy of Umedaptanib Pegol in Achondroplasia Trial
9M ago
4591
Ribomic Inc. Reports Continued Losses in Q1 2025
PremiumCompany Announcements
Ribomic Inc. Reports Continued Losses in Q1 2025
9M ago
4591
RIBOMIC to Launch Phase III Trial for Achondroplasia Drug in 2026
PremiumCompany AnnouncementsRIBOMIC to Launch Phase III Trial for Achondroplasia Drug in 2026
10M ago
4591
Ribomic Inc. Reports Continued Net Loss for Fiscal Year 2025
Premium
Company Announcements
Ribomic Inc. Reports Continued Net Loss for Fiscal Year 2025
1y ago
4591
Ribomic Inc. Reports Improved Financial Results for Nine Months Ending December 2024
Premium
Company Announcements
Ribomic Inc. Reports Improved Financial Results for Nine Months Ending December 2024
1y ago
4591
Ribomic Sees Reduced Losses in Latest Financial Report
PremiumCompany Announcements
Ribomic Sees Reduced Losses in Latest Financial Report
2y ago
4591
Ribomic Inc. Reports Quarterly Loss, Stable Assets
PremiumCompany Announcements
Ribomic Inc. Reports Quarterly Loss, Stable Assets
2y ago
4591
RIBOMIC Advances Pediatric Achondroplasia Treatment Study
PremiumCompany Announcements
RIBOMIC Advances Pediatric Achondroplasia Treatment Study
2y ago
4591

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >